



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION



C18 3'-sulfo Galactosylceramide (d18:1/18:0)

Item No. 24863

CAS Registry No.: 244215-65-4

Formal Name: N-[(1S,2R,3E)-2-hydroxy-1-[[[(3-O-sulfo- β -D-galactopyranosyl)oxy]methyl]-3-heptadecen-1-yl]-octadecanamide

Synonym: 3'-sulfo Galactosylceramide (d18:1/18:0), (3'-sulfo)Gal β -Cer(d18:1/18:0), N-Octadecanoyl Sulfatide, C18 Sulfatide

MF: C₄₂H₈₁NO₁₁S


FW: 808.2

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

C18 3'-sulfo Galactosylceramide (d18:1/18:0) is supplied as a solid. A stock solution may be made by dissolving the C18 3'-sulfo Galactosylceramide (d18:1/18:0) in the solvent of choice. C18 3'-sulfo galactosylceramide (d18:1/18:0) is soluble in a 5:1 solution of chloroform:methanol.

Description

C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. Levels of short-chain sulfatides, including C18 3'-sulfo galactosylceramide, decrease with age in mice and humans.^{1,2} It is increased in brain from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions.^{1,3} Plasma levels of C18 3'-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale.⁴ It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).⁵

References

1. Isaac, G., Pernber, Z., Giesemann, V., et al. Sulfatide with short fatty acid dominates in astrocytes and neurons. *FEBS J.* **273**(8), 1782-1790 (2006).
2. Svennerholm, L. and Ställberg-Stenhagen, S. Changes in the fatty acid composition of cerebrosides and sulfatides of human nervous tissue with age. *J. Lipid Res.* **9**(2), 215-225 (1968).
3. Moyano, A.L., Li, G., Lopez-Rosas, A., et al. Distribution of C16:0, C18:0, C24:1, and C24:0 sulfatides in central nervous system lipid rafts by quantitative ultra-high-pressure liquid chromatography tandem mass spectrometry. *Anal. Biochem.* **467**, 31-39 (2014).
4. Moyano, A.L., Pituch, K., Li, G., et al. Levels of plasma sulfatides C18 : 0 and C24 : 1 correlate with disease status in relapsing-remitting multiple sclerosis. *J. Neurochem.* **127**(5), 600-604 (2013).
5. Saville, J.T., Smith, N.J.C., Fletcher, J.M., et al. Quantification of plasma sulfatides by mass spectrometry: Utility for metachromatic leukodystrophy. *Anal. Chim. Acta* **955**, 79-85 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 - USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM